bluebird bio Announces Receipt of Expected Notices from Nasdaq
24 August 2024 - 6:05AM
Business Wire
bluebird bio, Inc. (Nasdaq: BLUE) today announced that it
received notices (the “notices”) on August 20, 2024 from The Nasdaq
Stock Market LLC (“Nasdaq”) stating that because the Company has
not yet filed its Quarterly Reports on Form 10-Q for each of the
quarters ended March 31, 2024 (the “Q1 2024 Form 10-Q”) and June
30, 2024 (the “Q2 2024 Form 10-Q”), it is not in compliance with
Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires listed
companies to timely file all required periodic financial reports
with the Securities and Exchange Commission (the “SEC”).
The notices have no immediate effect on the listing or trading
of the Company’s common stock on the Nasdaq.
The Company previously announced on April 26, 2024, that it was
not in compliance with the Rule due to the delay in filing its
Annual Report on Form 10-K for the year ended December 31, 2023
(the “2023 Form 10-K”). The Company subsequently submitted a plan
to Nasdaq to regain compliance with the Rule on or before October
14, 2024, within 180 calendar days from the prescribed due date of
its 2023 Form 10-K. Under Nasdaq rules, the Company must also file
its Q1 2024 Form 10-Q and Q2 2024 Form 10-Q within this same
period, and must submit an update to its plan to regain compliance
by September 4, 2024.
On March 26, 2024, bluebird announced that it will restate its
consolidated financial statements as of and for the year ended
December 31, 2022, and for each of the first three quarters of 2022
and 2023 in its 2023 Form 10-K. As a result of the restatement, the
Company is delayed in filing its 2023 Form 10-K and its Q1 2024
Form 10-Qand Q2 2024 Form 10-Q. The Company is continuing to work
expeditiously to complete these filings.
About bluebird bio, Inc.
bluebird bio is pursuing curative gene therapies to give
patients and their families more bluebird days.
Founded in 2010, bluebird has been setting the standard for gene
therapy for more than a decade—first as a scientific pioneer and
now as a commercial leader. bluebird has an unrivaled track record
in bringing the promise of gene therapy out of clinical studies and
into the real-world setting, having secured FDA approvals for three
therapies in under two years. Today, we are proving and scaling the
commercial model for gene therapy and delivering innovative
solutions for access to patients, providers, and payers.
With a dedicated focus on severe genetic diseases, bluebird has
the largest and deepest ex-vivo gene therapy data set in the field,
with industry-leading programs for sickle cell disease,
β-thalassemia and cerebral adrenoleukodystrophy. We custom design
each of our therapies to address the underlying cause of disease
and have developed in-depth and effective analytical methods to
understand the safety of our lentiviral vector technologies and
drive the field of gene therapy forward.
bluebird continues to forge new paths as a standalone commercial
gene therapy company, combining our real-world experience with a
deep commitment to patient communities and a people-centric culture
that attracts and grows a diverse flock of dedicated birds.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements that are not statements of historical facts
are, or may be deemed to be, forward-looking statements, such as
statements regarding the Company’s restatement of certain
historical financial statements, the filing of its 2023 Form 10-K,
Q1 2024 Form 10-Q and Q2 2024 Form 10-Q, and submission of an
update to its plan to regain compliance with the Rule, and the
expected timing thereof. Such forward-looking statements are based
on historical performance and current expectations and projections
about bluebird’s future goals, plans and objectives and involve
inherent risks, assumptions and uncertainties, including internal
or external factors that could delay, divert or change any of them
in the next several years, that are difficult to predict, may be
beyond bluebird’s control and could cause bluebird’s future goals,
plans and objectives to differ materially from those expressed in,
or implied by, the statements. No forward-looking statement can be
guaranteed. Forward-looking statements in this press release should
be evaluated together with the many risks and uncertainties that
affect bluebird bio’s business, particularly those identified in
the risk factors discussion in bluebird bio’s Annual Report on Form
10-K for the year ended December 31, 2022, as updated by its
subsequent Quarterly Reports on Form 10-Q, Current Reports on Form
8-K and other filings with the SEC. The forward-looking statements
included in this document are made only as of the date of this
document and except as otherwise required by applicable law,
bluebird bio undertakes no obligation to publicly update or revise
any forward-looking statement, whether as a result of new
information, future events, changed circumstances or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240823097360/en/
Investors: Courtney O’Leary, 978-621-7347
coleary@bluebirdbio.com Media: Jess Rowlands, 857-299-6103
jess.rowlands@bluebirdbio.com
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Sep 2024 to Oct 2024
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Oct 2023 to Oct 2024